Your browser doesn't support javascript.
loading
Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.
Brouckaert, Olivier; Rudolph, Anja; Laenen, Annouschka; Keeman, Renske; Bolla, Manjeet K; Wang, Qin; Soubry, Adelheid; Wildiers, Hans; Andrulis, Irene L; Arndt, Volker; Beckmann, Matthias W; Benitez, Javier; Blomqvist, Carl; Bojesen, Stig E; Brauch, Hiltrud; Brennan, Paul; Brenner, Hermann; Chenevix-Trench, Georgia; Choi, Ji-Yeob; Cornelissen, Sten; Couch, Fergus J; Cox, Angela; Cross, Simon S; Czene, Kamila; Eriksson, Mikael; Fasching, Peter A; Figueroa, Jonine; Flyger, Henrik; Giles, Graham G; González-Neira, Anna; Guénel, Pascal; Hall, Per; Hollestelle, Antoinette; Hopper, John L; Ito, Hidemi; Jones, Michael; Kang, Daehee; Knight, Julia A; Kosma, Veli-Matti; Li, Jingmei; Lindblom, Annika; Lilyquist, Jenna; Lophatananon, Artitaya; Mannermaa, Arto; Manoukian, Siranoush; Margolin, Sara; Matsuo, Keitaro; Muir, Kenneth; Nevanlinna, Heli; Peterlongo, Paolo.
Afiliação
  • Brouckaert O; Department of Obstetrics and Gynaecology, Jan Yperman Hospital, Ypres, Belgium.
  • Rudolph A; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Laenen A; Centre for Biostatistics and Statistical Bioinformatics, KU Leuven, Leuven, Belgium.
  • Keeman R; Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.
  • Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care University of Cambridge, Cambridge, UK.
  • Wang Q; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care University of Cambridge, Cambridge, UK.
  • Soubry A; Epidemiology Research Unit, Department of Public Health and Primary Care, Faculty of Medicine, KU Leuven - University of Leuven, Leuven, Belgium.
  • Wildiers H; Department of Oncology, Leuven Multidisciplinary Breast Cancer, University Hospital Leuven, KU Leuven, Leuven, Belgium.
  • Andrulis IL; Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada.
  • Arndt V; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
  • Beckmann MW; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Benitez J; Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Blomqvist C; Human Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid, Spain.
  • Bojesen SE; Centro de Investigación en Red de Enfermedades Raras, Valencia, Spain.
  • Brauch H; Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Brennan P; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Brenner H; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Chenevix-Trench G; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Choi JY; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Cornelissen S; University of Tübingen, Tübingen, Germany.
  • Couch FJ; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Cox A; International Agency for Research on Cancer, Lyon, France.
  • Cross SS; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Czene K; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Eriksson M; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Fasching PA; Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Figueroa J; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
  • Flyger H; Cancer Research Institute, Seoul National University, Seoul, Korea.
  • Giles GG; Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.
  • González-Neira A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Guénel P; Sheffield Cancer Research, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
  • Hall P; Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, UK.
  • Hollestelle A; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Hopper JL; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Ito H; Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Jones M; David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, USA.
  • Kang D; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh, UK.
  • Knight JA; Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Kosma VM; Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Australia.
  • Li J; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global health, The University of Melbourne, Melbourne, Australia.
  • Lindblom A; Human Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid, Spain.
  • Lilyquist J; Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, France.
  • Lophatananon A; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Mannermaa A; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Manoukian S; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global health, The University of Melbourne, Melbourne, Australia.
  • Margolin S; Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Matsuo K; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Muir K; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
  • Nevanlinna H; Cancer Research Institute, Seoul National University, Seoul, Korea.
  • Peterlongo P; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.
Breast Cancer Res ; 19(1): 119, 2017 Nov 07.
Article em En | MEDLINE | ID: mdl-29116004
ABSTRACT

BACKGROUND:

Previous studies have shown that reproductive factors are differentially associated with breast cancer (BC) risk by subtypes. The aim of this study was to investigate associations between reproductive factors and BC subtypes, and whether these vary by age at diagnosis.

METHODS:

We used pooled data on tumor markers (estrogen and progesterone receptor, human epidermal growth factor receptor-2 (HER2)) and reproductive risk factors (parity, age at first full-time pregnancy (FFTP) and age at menarche) from 28,095 patients with invasive BC from 34 studies participating in the Breast Cancer Association Consortium (BCAC). In a case-only analysis, we used logistic regression to assess associations between reproductive factors and BC subtype compared to luminal A tumors as a reference. The interaction between age and parity in BC subtype risk was also tested, across all ages and, because age was modeled non-linearly, specifically at ages 35, 55 and 75 years.

RESULTS:

Parous women were more likely to be diagnosed with triple negative BC (TNBC) than with luminal A BC, irrespective of age (OR for parity = 1.38, 95% CI 1.16-1.65, p = 0.0004; p for interaction with age = 0.076). Parous women were also more likely to be diagnosed with luminal and non-luminal HER2-like BCs and this effect was slightly more pronounced at an early age (p for interaction with age = 0.037 and 0.030, respectively). For instance, women diagnosed at age 35 were 1.48 (CI 1.01-2.16) more likely to have luminal HER2-like BC than luminal A BC, while this association was not significant at age 75 (OR = 0.72, CI 0.45-1.14). While age at menarche was not significantly associated with BC subtype, increasing age at FFTP was non-linearly associated with TNBC relative to luminal A BC. An age at FFTP of 25 versus 20 years lowered the risk for TNBC (OR = 0.78, CI 0.70-0.88, p < 0.0001), but this effect was not apparent at a later FFTP.

CONCLUSIONS:

Our main findings suggest that parity is associated with TNBC across all ages at BC diagnosis, whereas the association with luminal HER2-like BC was present only for early onset BC.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / História Reprodutiva Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / História Reprodutiva Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article